Table 2.
Disease probability according to multiple antibody presence in CTD
| Autoantibody combination | Probability (%) | Autoantibody combination | Probability (%) | ||
|---|---|---|---|---|---|
| SLE | dsDNA alone | 42.3 | lcSSc | CENP-B alone | 85.3 |
| dsDNA+Sm | 52.1 | CENP-B+Fibrillarin | 93.3 | ||
| dsDNA+Sm+ U1RNP | 96.9 | CENP-B+Fibrillarin+PM1 alfa | 99.1 | ||
| dsDNA+Sm+ U1RNP+Ro60 | 99.6 | CENP-B+Fibrillarin+PM1 alfa+U1RNP | 99.8 | ||
| dsDNA+Sm+ U1RNP+Ro60+Rib P | 99.8 | ||||
| dsDNA+Sm+ U1RNP+Ro60+Rib P+Ro52 | 100 | dcSSc | Scl70 alone | 79.2 | |
| Scl70+Fibrillarin | 87.3 | ||||
| IIM | Jo1 alone | 89.1 | Scl70+Fibrillarin+PM1 alfa | 97.4 | |
| Jo1+MSA | 99.7 | Scl70+Fibrillarin+PM1 alfa+U1RNP | 99.2 | ||
| Jo1+MSA+Ro52 | 100 | ||||
| lcSSc or dcSSc | RNApIII alone | 82.3 | |||
| pSS | Ro60 alone | 42.8 | RNApIII +Fibrillarin | 86.1 | |
| Ro60+Ro52 | 95.6 | RNApIII +Fibrillarin+PM1 alfa | 96.2 | ||
| Ro60+Ro52+La | 98.9 | RNApIII +Fibrillarin+PM1 alfa+U1RNP | 98.6 |
SLE systemic lupus erythematosus, SSc systemic sclerosis, lcSSc limited cutaneous SSc, dcSSc diffuse cutaneous SSc, pSS primary Sjögren’s syndrome, IIM idiopathic inflammatory myositis, UCTD undifferentiated connective tissue disease